Black Race Coefficient in GFR Estimation and Diabetes Medications in CKD: National Estimates

医学 糖尿病 估计 种族(生物学) 肾功能 内科学 泌尿科 内分泌学 生物 经济 植物 管理
作者
Carl P. Walther,Wolfgang C. Winkelmayer,Sankar D. Navaneethan
出处
期刊:Journal of The American Society of Nephrology 卷期号:32 (6): 1319-1321 被引量:10
标识
DOI:10.1681/asn.2020121724
摘要

GFR from serum creatinine–based equations informs medication management in CKD. These equations include age, sex, and race (Black versus non-Black), and the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation increases eGFR by approximately 16% for Black persons.1 This has led to concern about systematically different care; however, removal of the race factor has led to concern about medication eligibility and dosing.1 Glucose-lowering medication recommendations in CKD depend on eGFR. The Kidney Disease Improving Global Outcomes (KDIGO) Guideline for Diabetes Management in CKD recommends medication classes for CKD.2 Metformin is the first-line medication for type 2 diabetes in general, yet has a lower eGFR threshold (30 ml/min per 1.73 m2). Sodium-glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide 1 receptor agonists (GLP-1ras) have shown kidney and cardiovascular benefits and are preferred in CKD.2 However, the KDIGO guideline outlines lower eGFR limits for initiation (30 ml/min per 1.73 m2 for SGLT2i and 15 ml/min per 1.73 m2 for GLP-1ra).2 Removal of the race coefficient from eGFR for Black persons means some would newly qualify for CKD-preferred medications (eGFR reduced into CKD range) and some would no longer qualify (eGFR reduced below thresholds). We estimated the proportion of Black adults in the United States with type 2 diabetes for whom medication recommendations could be affected by dropping the eGFR race coefficient. We used the National Health and Nutrition Examination Survey (NHANES), a study that enables estimates of the United States population. NHANES was approved by the National Center for Health Statistics institutional review board. We combined four 2-year data cycles, 2011–2018, adjusted the weights and applied survey methods to estimate cross-sectional totals and proportions of the population.3 We included persons aged ≥20 years with self-reported Black race and type 2 diabetes. GFR estimates used CKD-EPI, and CKD was classified using eGFR and albuminuria.4 We further classified by metformin, SGLT2i, and GLP-1ra recommendations from the KDIGO diabetes guideline.2 For those reclassified as having CKD when the race coefficient was omitted, we estimated the proportion with prior indication for SGLT2i or a GLP-1ra based on the American Diabetes Association guideline (for cardiovascular disease or weight loss). Multiple imputation was performed for missing laboratory data (Supplemental References). We identified 923 observations, representing a cross-sectional estimate of 4,007,966 (95% confidence interval [95% CI], 3,358,243 to 4,657,689) Black adults with type 2 diabetes (Supplemental Table 1). Using race-based eGFR and albuminuria classification, 39.3% (95% CI, 36.2% to 42.4%) were classified as having CKD. This increased to 45.2% (95% CI, 41.9% to 48.5%) using eGFR without the race coefficient. This was an additional 5.9% (95% CI, 4.4% to 7.3%) of the study population classified with CKD—an estimated 235,341 (95% CI, 158,920 to 311,762) individuals. SGLT2i initiation (by the CKD guideline) would be recommended for 35.3% (95% CI, 32.4% to 38.2%) of Black persons with diabetes under race-based GFR estimation, versus 40.3% (95% CI, 37.4% to 43.2%) using eGFR without the race coefficient. GFR without race coefficient would reclassify 0.8% (95% CI, 0.1% to 1.4%) of Black persons with diabetes <30 ml/min per 1.73 m2, too low for SGLT2i initiation or metformin continuation, and 0.3% (95% CI, 0.0% to 0.7%) would drop <15 ml/min per 1.73 m2, too low for GLP-1ra. Of those newly classified with CKD, 27.8% (95% CI, 15.0% to 40.6%) would qualify for SGLT2i or GLP-1ra for cardiovascular indications, and 93.4% (95% CI, 86.0% to 100%) would qualify for weight loss (body mass index >25 kg/m2). Figure 1 presents results in a visual format.Figure 1.: Estimated proportions of Black adults with type 2 diabetes in the US, categorized by CKD status. (A) Tree map representing Black adults with type 2 diabetes in the United States categorized by KDIGO CKD group with eGFR estimated without race coefficient. The areas of the colored rectangles are proportional to the estimated number in each group. The bracket labeled “CKD” identifies the groups that would be considered to have CKD on the basis of eGFR and albuminuria (all groups except the green rectangle). The bright rectangles (with asterisks) represent proportions that undergo CKD classification into a more severe CKD group that could influence diabetes treatment when eGFR is calculated without race coefficient (versus eGFR with race coefficient). (B) Groups undergoing reclassification into a relevant higher CKD stage (eGFR calculated without versus with race coefficient) are highlighted here (same groups and scale as in (A)). Classifications use the KDIGO CKD classification on the basis of eGFR (G1/G2: ≥60 ml/min per 1.73 m2; G3a: 45–59 ml/min per 1.73 m2; G3b: 30–44 ml/min per 1.73 m2; G4: 15–29 ml/min per 1.73 m2; G5: <15 ml/min per 1.73 m2) and urine albumin-creatinine ratio (A1: <30 mg/g; A2: 30–300 mg/g; A3: >300 mg/g).4 eGFR was estimated using the CKD-EPI creatinine equation without race coefficient. The colors (green, yellow, orange, and red) correspond to the KDIGO CKD classification table, where movement from green to red represents worse prognosis. The total area of the colored rectangles in (A) represents an estimated 4,007,966 (95% CI, 3,358,243 to 4,657,689) persons.We found that omitting the eGFR race coefficient could affect guideline-directed medications for a substantial number of Black adults with type 2 diabetes. An additional one in 20 would be newly classified as having CKD and would potentially qualify for CKD-preferred glucose-lowering therapy. However, most reclassified into CKD had other indications for these agents: one in four for cardiovascular indications and nine in ten for weight loss. Nearly one in 100 would have eGFR reduction substantial enough to no longer qualify for SGLT2i initiation (on the basis of the KDIGO guideline) or metformin continuation. The effect of eGFR without the race coefficient has been noted previously with metformin therapy: 12%–16% of Black persons in a health database with eGFR 30–44 ml/min per 1.73 m2 prescribed metformin would no longer be eligible.5 Of note, equitable care in diabetes reduced incident CKD in Black persons to rates lower than White persons in the Action to Control Cardiovascular Risk in Diabetes trial.6 Disease classifications have important effects beyond medication eligibility, influencing anxiety and insurability. Our study has important limitations. The weights were not derived for the subpopulation of interest, and our subpopulation was small, resulting in wide 95% CIs. We were limited to single laboratory measurements. Black persons who also identified as Hispanic or multiracial persons were not identified. Our study does not address how race coefficient removal affects eGFR accuracy. Removal of the race coefficient has been associated with systematic underestimation of measured GFR among Black persons.7 The most important consideration is not guideline drug eligibility, nor accuracy of equations, but how to achieve optimal, equitable outcomes for Black persons. Enrollment of more Black participants in clinical trials is essential for this goal. Further investigations into medication effectiveness and safety in these individuals are needed. Disclosures S.D. Navaneethan reports personal fees from Bayer, Boehringer-Ingelheim, REATA, and Tricida; reports receiving research funding from the Department of Veterans Affairs Health Services Research & Development (1I01HX002917-01A1); reports receiving grants from the National Institutes of Health (NIDDK-R01DK101500) and Keryx, outside the submitted work; reports employment with US Department of Veterans Affairs; honoraria from Bayer, Boehringer Ingelheim, and Tricida; scientific advisor or membership with American Journal of Kidney Diseases, American Journal of Nephrology, CardioRenal Medicine, CJASN, Current Opinion in Nephrology and Hypertension, and KDIGO (guideline writing committee member). W.C. Winkelmayer reports personal fees from Akebia, AstraZeneca, Bayer, Janssen, Merck, and Vifor FMC Renal Pharma (including Relypsa) outside the submitted work. W.C. Winkelmayer also reports consultancy agreements with Akebia, AstraZeneca, Bayer, Otsuka, and Reata; honoraria form Akebia, AstraZeneca, Bayer, Otsuka, and Reata; scientific advisor or membership with American Journal of Kidney Diseases (editorial board member), American Journal of Nephrology (editorial board member), CJASN (editorial board member), Journal of the American Medical Association (associate editor), KDIGO (cochair), and Seminars in Dialysis (editorial board member). The remaining author has nothing to disclose. Funding C.P. Walther is supported in part by National Institute of Diabetes and Digestive and Kidney Diseases grant K23DK122131.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
3秒前
song完成签到 ,获得积分10
4秒前
怡然小蚂蚁完成签到 ,获得积分10
4秒前
小橙子完成签到,获得积分10
6秒前
SciGPT应助滴答采纳,获得10
6秒前
大气白翠完成签到,获得积分10
7秒前
确幸完成签到,获得积分10
7秒前
zjhzslq完成签到,获得积分10
7秒前
xdc发布了新的文献求助10
8秒前
ommphey完成签到 ,获得积分10
8秒前
牛哥还是强啊完成签到 ,获得积分10
9秒前
科研通AI2S应助屈岂愈采纳,获得10
10秒前
好名字完成签到,获得积分10
11秒前
kongzhiqiqi完成签到,获得积分10
12秒前
滴答完成签到 ,获得积分10
12秒前
浅浅殇完成签到,获得积分10
16秒前
17秒前
19秒前
滴答发布了新的文献求助10
22秒前
高高的天亦完成签到 ,获得积分10
23秒前
星空完成签到 ,获得积分10
24秒前
文艺的青旋完成签到 ,获得积分10
24秒前
青黛完成签到 ,获得积分10
31秒前
大橙子发布了新的文献求助10
35秒前
领导范儿应助科研通管家采纳,获得10
36秒前
量子星尘发布了新的文献求助10
40秒前
明钟达完成签到 ,获得积分10
48秒前
byyyy完成签到,获得积分10
51秒前
高高的哈密瓜完成签到 ,获得积分10
55秒前
Rondab应助橙汁采纳,获得10
58秒前
读书的时候完成签到,获得积分10
1分钟前
颜云尔完成签到,获得积分10
1分钟前
孤独雨梅完成签到,获得积分10
1分钟前
woobinhua完成签到 ,获得积分10
1分钟前
雪落你看不见完成签到,获得积分10
1分钟前
十月天秤完成签到,获得积分0
1分钟前
依文完成签到,获得积分20
1分钟前
ymr完成签到 ,获得积分10
1分钟前
哦哦哦完成签到 ,获得积分10
1分钟前
jzmupyj完成签到,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038128
求助须知:如何正确求助?哪些是违规求助? 3575831
关于积分的说明 11373827
捐赠科研通 3305610
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022